| 1 | Alpha-fetoprotein,protein induced by vitamin K absence or antagonist-Ⅱ,lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease:A multicenter analysis显示文摘Background:Current surveillance strategies for hepatocellular carcinoma(HCC)among patients with non-alcoholic fatty liver disease(NAFLD)are insufficient.This study aimed to investigate the diagnostic perfor-mance of alpha-fetoprotein(AFP),protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ),lens culinaris agglutinin-reactive fraction of AFP(AFP-L3),and their combinations in HCC underlying NAFLD patients.Methods:Serologic AFP,AFP-L3,and PIVKA-Ⅱ levels in NAFLD patients with and without HCC were mea-sured.By receiver operating characteristic(ROC)analyses,the area under the curve(AUC),sensitivity,and specificity were obtained to evaluate the diagnostic accuracy of each biomarker and their combinations.Results:This study was conducted on 139 patients with NAFLD-HCC and 345 NAFLD controls.The eleva-tion of these three biomarkers was observed in patients with NAFLD-HCC compared to those in NAFLD controls(all P<0.001).When they were analyzed individually,PIVKA-Ⅱ showed the best performance in diagnosing any-stage HCC with an AUC of 0.869,followed by AFP(0.763;vs.PIVKA-Ⅱ,P<0.001)and AFP-L3(0.689;vs.PIVKA-II,P<0.001).When they were analyzed in combination,AFP+PIVKA-Ⅱ yielded the highest AUC(0.906),followed by AFP+PIVKA-II+AFP-L3(0.904;vs.AFP+PIVKA-Ⅱ,P=0.086),PIVKA-Ⅱ+AFP-L3(0.881;vs.AFP+PIVKA-II,P<0.001),and AFP+AFP-L3(0.759;vs.AFP+PIVKA-II,P<0.001).Similar findings were obtained in the subgroup with early-stage NAFLD-HCC,as well as the non-cirrhotic subgroup.Conclusions:These data validated the better diagnostic ability of PIVKA-II than AFP or AFP-L3 alone for diagnosing any-stage HCC among patients with NAFLD,and the combination of AFP+PIVKA-II signifi-cantly improved the diagnostic accuracy of NAFLD-HCC. | Ming-Cheng Guan Wei Ouyang Si-Yu Liu Li-Yang Sun Wei-Yue Chen Xiang-Min Tong Hong Zhu Tian Yang | 2022 | Hepatobiliary & Pancreatic Diseases International2022，21，6： | 2 |
| 2 | 早期肝细胞癌:肝切除和局部热消融是互相竞争还是相辅相成显示文摘肝切除、局部热消融(LTAT)是治疗肝细胞癌最常用的治愈性手段。早期肝细胞癌(肿瘤直径≤3 cm)既是肝切除的最佳适应证,更是LTAT的最优势领域,对于其治疗首选肝切除还是LTAT,一直是一个争论性话题。近二十多年来,随着微创理念的建立、设备的改进、技术的提升和经验的积累,肝切除治疗早期肝细胞癌的微创性、安全性和疗效进一步提升。相比而言,LTAT治疗早期肝细胞癌在质量管理、理念和技术等方面缺乏创新性进步和体系性推进,总体疗效缺乏实质性提升,学术地位受到了挑战。本文从早期肝细胞癌肝切除和LTAT的特点、影响治疗决策的原因、未来治疗模式的展望等方面,简述肝切除和LTAT在早期肝细胞癌综合治疗的学术地位和相互关系,指出在我国现阶段,肝切除和LTAT对于早期肝细胞癌的治疗存在着很大的互补性,两者的关系不是互相竞争,而是互相补充、相辅相成。 | 孙文兵 | 2022 | 国际外科学杂志2022，49，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员